FACTANKER · measured, cited, anchored official records connected

Bone Biologics Corporation — Net Income by Fiscal Year

21 fiscal years, as filed with the SEC; every row links its evidence fact.

Cite as: FACTANKER, https://factanker.com/entity/2c2dfc61-8b87-4560-bfcb-c65996fd8479/serie/net-income

Fiscal yearNet IncomePeriodEvidence
FY 2025$-3.1M2025-01-01 – 2025-12-31evidence 0001493152-26-008564
FY 2024$-4.1M2024-01-01 – 2024-12-31evidence 0001493152-25-008383
FY 2023$-8.9M2023-01-01 – 2023-12-31evidence 0001493152-24-007432
FY 2022$-1.5M2022-01-01 – 2022-12-31evidence 0001493152-23-009799
FY 2021$-1.6M2021-01-01 – 2021-12-31evidence 0001493152-22-006850
FY 2020$-1.8M2020-01-01 – 2020-12-31evidence 0001493152-21-008887
FY 2019$-3.4M2019-01-01 – 2019-12-31evidence 0001493152-20-004977
FY 2018$-4.4M2018-01-01 – 2018-12-31evidence 0001493152-19-004221
FY 2017$-60.6M2007-10-18 – 2018-03-31evidence 0001493152-18-006922
FY 2016$50.0M2007-10-18 – 2017-03-31evidence 0001493152-17-005163
FY 2015$32.9M2004-03-09 – 2016-03-31evidence 0001493152-16-009706
FY 2014$12.0M2004-03-09 – 2015-03-31evidence 0001493152-15-001976
FY 2013$-68.6k2007-10-18 – 2014-04-30evidence 0001376474-14-000220
FY 2012$-62.7k2007-10-18 – 2013-04-30evidence 0001493152-13-001189
FY 2011$-57.5k2007-10-19 – 2012-04-30evidence 0001387131-12-001886
FY 2010$-897.7k2010-01-01 – 2010-12-31evidence 0001493152-14-003110
FY 2009$-1.2M2009-01-01 – 2009-12-31evidence 0001493152-14-003110
FY 2008$-1.0M2008-01-01 – 2008-12-31evidence 0001493152-14-003110
FY 2007$-1.2M2007-01-01 – 2007-12-31evidence 0001493152-14-003110
FY 2006$-476.5k2006-01-01 – 2006-12-31evidence 0001493152-14-003110
FY 2005$-50.8k2005-01-01 – 2005-12-31evidence 0001493152-14-003110
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).

Bone Biologics Corporation — all facts · Revenue · Operating Income